CA
GILD icon

Cullinan Associates’s Gilead Sciences GILD Stock Holding History

Cullinan Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$597K Sell
4,286
-376
-8% -$52.7K 0.05% 149
2025
Q4 		$572K Buy
4,662
+85
+2% +$10.3K 0.04% 154
2025
Q3 		$508K Sell
4,577
-2,572
-36% -$292K 0.03% 165
2025
Q2 		$793K Sell
7,149
-418
-6% -$44.5K 0.05% 140
2025
Q1 		$848K Sell
7,567
-7,574
-50% -$782K 0.06% 135
2024
Q4 		$1.4M Sell
15,141
-85,844
-85% -$7.73M 0.09% 121
2024
Q3 		$8.72M Sell
100,985
-14,347
-12% -$1.09M 0.49% 47
2024
Q2 		$7.91M Sell
115,332
-23,956
-17% -$1.6M 0.45% 56
2024
Q1 		$10.2M Buy
139,288
+20,532
+17% +$1.58M 0.57% 46
2023
Q4 		$9.62M Sell
118,756
-12,396
-9% -$965K 0.54% 41
2023
Q3 		$9.83M Sell
131,152
-225
-0.2% -$17.3K 0.57% 45
2023
Q2 		$10.1M Buy
131,377
+2,737
+2% +$218K 0.56% 51
2023
Q1 		$10.7M Buy
128,640
+9,381
+8% +$777K 0.62% 47
2022
Q4 		$10.2M Sell
119,259
-30,923
-21% -$2.45M 0.57% 43
2022
Q3 		$9.27M Buy
150,182
+6,410
+4% +$404K 0.59% 47
2022
Q2 		$8.89M Buy
143,772
+10,229
+8% +$633K 0.54% 49
2022
Q1 		$7.94M Buy
133,543
+12,962
+11% +$829K 0.42% 66
2021
Q4 		$8.76M Buy
120,581
+23,070
+24% +$1.59M 0.45% 66
2021
Q3 		$6.81M Buy
97,511
+4,790
+5% +$337K 0.38% 75
2021
Q2 		$6.38M Buy
92,721
+554
+0.6% +$37K 0.36% 83
2021
Q1 		$5.96M Buy
92,167
+2,468
+3% +$159K 0.34% 81
2020
Q4 		$5.23M Sell
89,699
-7,110
-7% -$429K 0.31% 83
2020
Q3 		$6.12M Buy
96,809
+845
+0.9% +$58.6K 0.39% 67
2020
Q2 		$7.38M Buy
95,964
+583
+0.6% +$44.7K 0.52% 46
2020
Q1 		$7.13M Buy
95,381
+83,981
+737% +$5.8M 0.58% 44
2019
Q4 		$741K Buy
11,400
+6,900
+153% +$449K 0.05% 132
2019
Q3 		$285K Hold
4,500
– – 0.02% 164
2019
Q2 		$304K Hold
4,500
– – 0.02% 166
2019
Q1 		$293K Hold
4,500
– – 0.02% 163
2018
Q4 		$281K Sell
4,500
-3,100
-41% -$217K 0.02% 163
2018
Q3 		$587K Hold
7,600
– – 0.04% 145
2018
Q2 		$538K Sell
7,600
-3,450
-31% -$244K 0.04% 149
2018
Q1 		$833K Sell
11,050
-400
-3% -$31.8K 0.06% 138
2017
Q4 		$820K Buy
11,450
+200
+2% +$15.2K 0.06% 138
2017
Q3 		$911K Hold
11,250
– – 0.07% 137
2017
Q2 		$796K Hold
11,250
– – 0.06% 148
2017
Q1 		$764K Sell
11,250
-32,972
-75% -$2.32M 0.06% 152
2016
Q4 		$3.17M Sell
44,222
-6,620
-13% -$492K 0.27% 99
2016
Q3 		$4.02M Sell
50,842
-486
-0.9% -$39.5K 0.34% 80
2016
Q2 		$4.28M Buy
51,328
+1,406
+3% +$125K 0.35% 76
2016
Q1 		$4.59M Buy
49,922
+12,390
+33% +$1.12M 0.39% 71
2015
Q4 		$3.8M Buy
37,532
+2,250
+6% +$234K 0.33% 80
2015
Q3 		$3.46M Buy
35,282
+11,422
+48% +$1.27M 0.32% 74
2015
Q2 		$2.79M Sell
23,860
-1,510
-6% -$165K 0.23% 93
2015
Q1 		$2.49M Buy
+25,370
New +$2.58M 0.19% 104

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Cullinan Associates's GILD Position: Q1 2026 in Review

Cullinan Associates reduced its Gilead Sciences (GILD) stake by 8.1% in Q1 2026, selling an estimated $52.7K and leaving 4,286 shares worth $597K. The position accounts for 0.05% of the portfolio, ranked #149.

Cullinan Associates first reported a position in GILD in Q1 2015 and has held it in 45 quarters since. The position peaked at $10.7M in Q1 2023. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Cullinan Associates held 4,286 shares of Gilead Sciences worth $597K as of Q1 2026.
  • Cullinan Associates sold 376 Gilead Sciences shares in Q1 2026, an estimated $52.7K.
  • Gilead Sciences made up 0.05% of Cullinan Associates's portfolio in Q1 2026, its #149 holding.
  • Cullinan Associates first reported a position in Gilead Sciences in Q1 2015 and has held it in 45 quarters since.
  • Cullinan Associates's Gilead Sciences position peaked at $10.7M in Q1 2023.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Cullinan Associates's 13F filing for Q1 2026, filed 1 May 2026.